Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Jong Jin Sung"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma
Jong Jin Sung, Sang Jae Noh, Jun Sang Bae, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Woo Sung Moon
J Pathol Transl Med. 2016;50(1):52-57.   Published online November 18, 2015
DOI: https://doi.org/10.4132/jptm.2015.10.09
  • 8,942 View
  • 76 Download
  • 19 Web of Science
  • 16 Crossref
AbstractAbstract PDF
Background
Increasing evidence has shown that tumor initiation and growth are nourished by a small subpopulation of cancer stem cells (CSCs) within the tumor mass. CSCs are posited to be responsible for tumor maintenance, growth, distant metastasis, and relapse after curative operation. We examined the expression of CSC markers in paraffin-embedded tissue sections of hepatocellular carcinoma (HCC) and correlated the results with clinicopathologic characteristics. Methods: Immunohistochemical staining for the markers believed to be expressed in the CSCs, including epithelial cell adhesion molecule (EpCAM), keratin 19 (K19), CD133, and CD56, was performed in 82 HCC specimens. Results: EpCAM expression was observed in 56% of the HCCs (46/82) and K19 in 6% (5/82). EpCAM expression in HCC significantly correlated with elevated α-fetoprotein level, microvessel invasion of tumor cells, and high histologic grade. In addition, Ep- CAM expression significantly correlated with K19 expression. The overall survival and relapsefree survival rates in patients with EpCAM-expressing HCC were relatively lower than those in patients with EpCAM-negative HCC. All but two of the 82 HCCs were negative for CD133 and CD56, respectively. Conclusions: Our results suggest that HCCs expressing EpCAM are associated with unfavorable prognostic factors and have a more aggressive clinical course than those not expressing EpCAM. Further, the expression of either CD133 or CD56 in paraffin-embedded HCC tissues appears to be rare.

Citations

Citations to this article as recorded by  
  • Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma
    Narayanan Sadagopan, Aiwu Ruth He
    International Journal of Molecular Sciences.2024; 25(2): 1259.     CrossRef
  • Diagnostic value of expressions of cancer stem cell markers for adverse outcomes of hepatocellular carcinoma and their associations with prognosis: A Bayesian network meta‑analysis
    Zhengrong Ou, Shoushuo Fu, Jian Yi, Jingxuan Huang, Weidong Zhu
    Oncology Letters.2024;[Epub]     CrossRef
  • Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis
    Peiwen Ding, Panyu Chen, Jiqi Ouyang, Qiang Li, Shijie Li
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma
    Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli, Claudio Tiribelli
    International Journal of Molecular Sciences.2023; 24(17): 13357.     CrossRef
  • EpCAM, Ki67, and ESM1 Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation
    Aiat Shaban Hemida, Doha Maher Taie, Moshira Mohamed Abd El-Wahed, Mohammed Ibrahim Shabaan, Mona Saeed Tantawy, Nermine Ahmed Ehsan
    Applied Immunohistochemistry & Molecular Morphology.2023; 31(9): 596.     CrossRef
  • The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers
    Izabela Zarębska, Arkadiusz Gzil, Justyna Durślewicz, Damian Jaworski, Paulina Antosik, Navid Ahmadi, Marta Smolińska-Świtała, Dariusz Grzanka, Łukasz Szylberg
    Clinics and Research in Hepatology and Gastroenterology.2021; 45(3): 101664.     CrossRef
  • Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
    Zhouhong Ge, Jean C.A. Helmijr, Maurice P.H.M. Jansen, Patrick P.C. Boor, Lisanne Noordam, Maikel Peppelenbosch, Jaap Kwekkeboom, Jaco Kraan, Dave Sprengers
    Translational Oncology.2021; 14(7): 101073.     CrossRef
  • Hepatocellular Carcinoma Score and Subclassification Into Aggressive Subtypes Using Immunohistochemical Expression of p53, β-Catenin, CD133, and Ki-67
    Asmaa G. Abdou, Nanis S. Holah, Dina S. Elazab, Walaa G. El-Gendy, Mohammed T. Badr, Dalia R. Al-Sharaky
    Applied Immunohistochemistry & Molecular Morphology.2021; 29(1): 20.     CrossRef
  • The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma
    Keigo Murakami, Hiroyuki Kumata, Shigehito Miyagi, Takashi Kamei, Hironobu Sasano
    Pathology International.2021; 71(10): 682.     CrossRef
  • Predictors of recurrence and survival of hepatocellular carcinoma: A prospective study including transient elastography and cancer stem cell markers
    Hend Ibrahim Shousha, Rabab Fouad, Tamer Mahmoud Elbaz, Dina Sabry, Mohamed Mahmoud Nabeel, Ahmed Hosni Abdelmaksoud, Aisha Mahmoud Elsharkawy, Zeinab Abdellatif Soliman, Ghada Habib, Ashraf Omar Abdelaziz
    Arab Journal of Gastroenterology.2020; 21(2): 95.     CrossRef
  • Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma
    Ya Li, Qiuju Han, Huajun Zhao, Quanjuan Guo, Jian Zhang
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations
    An B. Luong, Huy Q. Do, Paola Tarchi, Deborah Bonazza, Cristina Bottin, Loraine Kay D. Cabral, Long D. C. Tran, Thao P. T. Doan, Lory S. Crocè, Hoa L. T. Pham, Claudio Tiribelli, Caecilia H. C. Sukowati
    Cells.2020; 9(12): 2672.     CrossRef
  • Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma
    Hirohisa Okabe, Tomoharu Yoshizumi, Yo-ichi Yamashita, Katsunori Imai, Hiromitsu Hayashi, Shigeki Nakagawa, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Toru Beppu, Shinichi Aishima, Ken Shirabe, Hideo Baba, Yoshihiko Maehara, Motoyuki
    PLOS ONE.2018; 13(9): e0203856.     CrossRef
  • Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma
    Chih‑Jan Ko, Chia‑Jung Li, Meng‑Yu Wu, Pei‑Yi Chu
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer
    Wanlu Li, Mi-Ra Lee, EunHee Choi, Mee-Yon Cho
    Journal of Pathology and Translational Medicine.2017; 51(1): 17.     CrossRef
  • PIN1 in hepatocellular carcinoma is associated with TP53 gene status
    Jun Sang Bae, Sang Jae Noh, Kyoung Min Kim, Kyu Yun Jang, Ho Sung Park, Myoung Ja Chung, Byung-Hyun Park, Woo Sung Moon
    Oncology Reports.2016; 36(4): 2405.     CrossRef
Brief Case Report
Nesidioblastosis and Pancreatic Non-functioning Islet Cell Tumor in an Adult with Type 2 Diabetes Mellitus
Ji Eun Choi, Sang Jae Noh, Jong Jin Sung, Woo Sung Moon
Korean J Pathol. 2013;47(5):489-491.   Published online October 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.489
  • 7,628 View
  • 67 Download
  • 9 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia
    Martin Philipp Dieterle, Ayman Husari, Sophie Nicole Prozmann, Hendrik Wiethoff, Albrecht Stenzinger, Manuel Röhrich, Uwe Pfeiffer, Wolfgang Rüdiger Kießling, Helena Engel, Harald Sourij, Thorsten Steinberg, Pascal Tomakidi, Stefan Kopf, Julia Szendroedi
    Biomedicines.2023; 11(6): 1732.     CrossRef
  • Postprandial hypoglycemia after upper gastrointestinal tract surgery: prevalence and pathophysiology (part 1)
    M. Yu. Yukina, M. O. Chernova, E. A. Troshina, V. V. Evdoshenko, N. M. Platonova
    Almanac of Clinical Medicine.2021; 49(4): 285.     CrossRef
  • Nésidioblastose traitée par pasiréotide LAR : à propos d’un cas
    Alexia Rouland, Benjamin Bouillet, Pauline Legris, Isabelle Simoneau, Jean-Michel Petit, Bruno Vergès
    Médecine des Maladies Métaboliques.2021; 15(6): 619.     CrossRef
  • Concurrent Adult-Onset Diffuse β-Cell Nesidioblastosis and Pancreatic Neuroendocrine Tumor: A Case Report and Review of the Literature
    Mushfig Orujov, Keith K. Lai, Catherine L. Forse
    International Journal of Surgical Pathology.2019; 27(8): 912.     CrossRef
  • Nesidioblastosis in an Adult with Short Gut Syndrome and Type 2 Diabetes
    Mimi Wong, Luke Conway, Caroline Cooper, Ashim Sinha, Nirjhar Nandi
    AACE Clinical Case Reports.2019; 5(6): e375.     CrossRef
  • Superimposed effect of ovariectomy on type 2 diabetes mellitus in Wistar rats
    Minerva K. Fahmy, Hayam G. Sayyed, Eman A. Abd Elrahim, Rana T.A. Farag
    Alexandria Journal of Medicine.2018; 54(2): 129.     CrossRef
  • Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma
    Keijiro Ueda, Ken Kawabe, Lingaku Lee, Yuichi Tachibana, Nao Fujimori, Hisato Igarashi, Yoshinao Oda, Robert T. Jensen, Ryoichi Takayanagi, Tetsuhide Ito
    Pancreas.2017; 46(4): 476.     CrossRef
  • Nesidioblastosis (diagnosis, surgical treatment)
    A. G. Kriger, A. V. Smirnov, D. V. Kalinin, A. V. Glotov, S. V. Berelavichus, G. I. Konyaeva, A. N. Lebedeva, N. A. Karel’skaya, V. N. Tsygankov
    Khirurgiya. Zhurnal im. N.I. Pirogova.2015; (10): 16.     CrossRef
  • A Rare Complication of Gastric Bypass (Weight Loss) Surgery
    Betül Ünal, Özlem Ceren Uzun, Cumhur İbrahim Başsorgun, Okan Erdoğan, Gülsüm Özlem Elpek
    International Journal of Surgical Pathology.2015; 23(1): 68.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP